Zacks Investment Research upgraded shares of Cascadian Therapeutics Inc. (NASDAQ:CASC) from a sell rating to a hold rating in a report published on Friday.

According to Zacks, “Cascadian Therapeutics, Inc. is a biopharmaceutical company specializing in developing innovative therapeutic product candidates for the treatment of cancer. The company’s product candidate is ONT-380, an orally active and selective small molecule HER2 inhibitor which is in preclinical trial stage. Cascadian Therapeutics, Inc., formerly known as Oncothyreon Inc., is headquartered in Seattle, Washington. “

CASC has been the topic of several other reports. Cowen and Company reaffirmed a buy rating on shares of Cascadian Therapeutics in a research note on Monday, October 10th. Jefferies Group reiterated a buy rating and set a $3.00 price objective on shares of Cascadian Therapeutics in a report on Tuesday, November 8th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $3.00.

Cascadian Therapeutics (NASDAQ:CASC) opened at 1.02 on Friday. The firm’s 50-day moving average is $1.15 and its 200 day moving average is $1.16. Cascadian Therapeutics has a 12-month low of $0.82 and a 12-month high of $3.75. The firm’s market cap is $138.02 million.

Cascadian Therapeutics (NASDAQ:CASC) last released its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by $0.01. Equities research analysts predict that Cascadian Therapeutics will post $5.02 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Cascadian Therapeutics Inc. (CASC) Upgraded to Hold by Zacks Investment Research” was first posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2016/11/28/cascadian-therapeutics-inc-casc-upgraded-to-hold-by-zacks-investment-research.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of CASC. ProShare Advisors LLC raised its position in Cascadian Therapeutics by 20.3% in the third quarter. ProShare Advisors LLC now owns 85,070 shares of the biopharmaceutical company’s stock valued at $140,000 after buying an additional 14,378 shares during the last quarter. KCG Holdings Inc. raised its stake in Cascadian Therapeutics by 204.6% in the third quarter. KCG Holdings Inc. now owns 137,775 shares of the biopharmaceutical company’s stock worth $226,000 after buying an additional 92,549 shares in the last quarter. Northern Trust Corp raised its stake in Cascadian Therapeutics by 23.3% in the third quarter. Northern Trust Corp now owns 162,455 shares of the biopharmaceutical company’s stock worth $267,000 after buying an additional 30,744 shares in the last quarter. Susquehanna International Group LLP raised its stake in Cascadian Therapeutics by 944.4% in the third quarter. Susquehanna International Group LLP now owns 250,788 shares of the biopharmaceutical company’s stock worth $411,000 after buying an additional 280,488 shares in the last quarter. Finally, BlackRock Institutional Trust Company N.A. raised its stake in Cascadian Therapeutics by 1.3% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 1,849,475 shares of the biopharmaceutical company’s stock worth $3,033,000 after buying an additional 23,406 shares in the last quarter. Hedge funds and other institutional investors own 64.18% of the company’s stock.

Cascadian Therapeutics Company Profile

Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.

5 Day Chart for NASDAQ:CASC

Receive News & Stock Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related stocks with our FREE daily email newsletter.